ClinicalTrials.gg
CompletedNCT01597622Updated Mar 27, 2020Results posted

BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

A Phase 3 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-27.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
15th of 36
142 · median 81
Started
2012
with 4 others
Phase 3
11 of 36
none open now
Registered
14th of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 15th largest by enrollment, is one of 5 that started in 2012, is one of 11 in phase 3, and was the 14th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This study provides subjects who complete the BEL113750 study and subjects who complete the open-label extension of HGS1006-C1115 (referred to as C1115) Study in Japan the option of continuing treatment with belimumab (10 mg/kg intravenously every 4 weeks) for those randomized to belimumab, or the option to begin treatment with belimumab for those randomized to placebo, as an add-on to their standard of care SLE therapy.

Read the detailed description

This is a multicentre, continuation study of belimumab plus standard of care (SOC) in SLE subjects who completed the Phase III BEL113750 protocol in Northeast Asia or who completed the open-label extension of the HGS1006-C1115 protocol in Japan. This study provides subjects who complete the BEL113750 study the option of continuing treatment with belimumab (10 mg/kg intravenously every 4 weeks) for those randomized to belimumab, or the option to begin treatment with belimumab for those randomized to placebo, as an add-on to their SOC SLE therapy. Subjects participating in this continuation protocol will continue to be monitored for safety and efficacy, as measured by the SLE responder index. Subjects who complete 48 weeks of treatment on the BEL113750 study and who meet inclusion/exclusion criteria, and provide informed consent, will be given the option to enter the continuation study. All subjects will receive belimumab 10 mg/kg IV infused over 1 hour every 4 weeks. Subjects recruited into this study will continue to receive treatment with belimumab until such time as belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SELENA
  • belimumab
  • Lupus
  • systemic lupus erythematosus
  • PGA
  • BLys
  • SLE Flare Index
  • continuation
  • phase III
  • BILAG
  • extension
  • efficacy
  • SRI
  • B cell
  • SLEDAI
  • safety
  • Asia
  • B lymphocyte
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed the BEL113750 Protocol in Northeast Asia through Week 48 OR have completed the open-label extension of C1115 in Japan.
  • Be able to receive the first dose of belimumab for BEL114333 four weeks (minimum of 2 weeks, maximum of 8 weeks) after the last dose in BEL113750 OR be able to receive the first dose of IV belimumab 1 week (plus a 1 week visit window) after the last dose of open-label SC belimumab in C1115..

Exclusion criteria

Exclusion Criteria:

  • Have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, or infectious diseases), or experienced an adverse event (AE) in the Phase 3 study that could, in the opinion of the principal investigator, put the subject at undue risk.
  • Have developed any other medical diseases (e.g., cardiopulmonary), laboratory abnormalities, or conditions (e.g., poor venous access) that in the opinion of the principal investigator, makes the subject unstable for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Open-label Belimumab

    Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.

    Drug: Belimumab

Interventions

  • 10 mg/kg administered intravenously over 1 hour every 4 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    Any untoward medical occurrence in participant, temporally associated with use of medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death,life threatening,requires hospitalization or prolongation of existing hospitalization,results in disability/incapacity,congenital anomaly/birth defect,medically important were categorized as SAE. Number of participants who had any AE(includes those having non-serious and/or serious AEs) or any SAE are presented.Treatment-emergent AEs are defined as AEs that started on or after first dose of belimumab treatment and for those participants who were randomized to placebo in parent study,ongoing AEs that started before first open-label belimumab dose(in either C1115 open-label extension or BEL114333),worsened (severity,seriousness,relatedness) at any point during the open-label treatment.Timeframe includes exposure in parent study/upto16 weeks post infusion in current study(114333).

    Time frame: Up to 6 calendar years and 9 months

Secondary outcomes

  1. Percentage of SLE Responder Index (SRI) Responders by Study Visit

    SRI response is composite index, defined as percent of participants with\>=4 point reduction from Baseline in safety of estrogen in lupus national assessment systemic lupus erythematosus disease activity index (SELENA-SLEDAI) score and no worsening (increase of \<0.30 points from Baseline) in physicians global assessment(PGA) \&no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0(no activity) to 3(severe activity). BILAG has no range. Baseline is last available value prior to first belimumab exposure. Year 8 Week 24 visit is the Exit Visit obtained by slotting the Exit Visit to Week 24. Timeframe includes exposure in parent study/upto 4 weeks post infusion (Exit visit) in current study (114333).

    Time frame: Study Years 1 to 7: At Week 24 and 48 Visits, Year 8: only Week 24 Visit

07

Results

Posted Jan 9, 2020

Participant flow

This was multicenter, open-label continuation study of belimumab plus standard of care (SOC) in Systemic Lupus Erythematosus (SLE) participants who completed study BEL113750 (NCT01345253) in Northeast Asia (Japan and Korea) \& participants who completed the open-label extension of C1115 (NCT01484496) in Japan to assess long term safety \& efficacy.

Participant flow — Overall Study
MilestoneOpen-label Belimumab 10 mg/kg
Started142
Completed104
Not completed38
Withdrew: Adverse event7
Withdrew: Lack of efficacy3
Withdrew: Protocol violation1
Withdrew: Lost to follow-up1
Withdrew: Investigator discretion5
Withdrew: Withdrawal by subject20
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

Any untoward medical occurrence in participant, temporally associated with use of medicinal product, whether or not considered related to medicinal product. Any untoward event resulting in death,life threatening,requires hospitalization or prolongation of existing hospitalization,results in disability/incapacity,congenital anomaly/birth defect,medically important were categorized as SAE. Number of participants who had any AE(includes those having non-serious and/or serious AEs) or any SAE are presented.Treatment-emergent AEs are defined as AEs that started on or after first dose of belimumab treatment and for those participants who were randomized to placebo in parent study,ongoing AEs that started before first open-label belimumab dose(in either C1115 open-label extension or BEL114333),worsened (severity,seriousness,relatedness) at any point during the open-label treatment.Timeframe includes exposure in parent study/upto16 weeks post infusion in current study(114333).

Time frame:
Up to 6 calendar years and 9 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsOpen-label Belimumab 10 mg/kg
Any SAEs48
Any AEs139
SecondaryPercentage of SLE Responder Index (SRI) Responders by Study Visit

SRI response is composite index, defined as percent of participants with\>=4 point reduction from Baseline in safety of estrogen in lupus national assessment systemic lupus erythematosus disease activity index (SELENA-SLEDAI) score and no worsening (increase of \<0.30 points from Baseline) in physicians global assessment(PGA) \&no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0(no activity) to 3(severe activity). BILAG has no range. Baseline is last available value prior to first belimumab exposure. Year 8 Week 24 visit is the Exit Visit obtained by slotting the Exit Visit to Week 24. Timeframe includes exposure in parent study/upto 4 weeks post infusion (Exit visit) in current study (114333).

Time frame:
Study Years 1 to 7: At Week 24 and 48 Visits, Year 8: only Week 24 Visit
Reported as:
Number · Percentage of Participants
Percentage of SLE Responder Index (SRI) Responders by Study Visit
Percentage of ParticipantsOpen-label Belimumab 10 mg/kg
Year 1 Week 24, n=13647.8
Year 1, Week 48, n=13351.1
Year 2, Week 24, n=12955.0
Year 2, Week 48, n=12153.7
Year 3, Week 24, n=10357.3
Year 3, Week 48, n=8868.2
Year 4, Week 24, n=8067.5
Year 4, Week 48, n=6076.7
Year 5, Week 24, n=3271.9
Year 5, Week 48, n=2969.0
Year 6, Week 24, n=2466.7
Year 6, Week 48, n=2268.2
Year 7, Week 24, n=1883.3
Year 7, Week 48, n=1384.6
Year 8, Week 24, n=1100

Adverse events

Collected over Treatment-emergent SAEs and non-serious AEs were collected up to maximum duration of 6 calendar years and 9 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Belimumab 10 mg/kg1/142 (0.7%)48/142 (33.8%)134/142 (94.4%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventOpen-label Belimumab 10 mg/kg
CellulitisInfections and infestations3/142
Herpes zosterInfections and infestations3/142
ContusionInjury, poisoning and procedural complications3/142
EndocarditisInfections and infestations2/142
Pyelonephritis acuteInfections and infestations2/142
PyrexiaGeneral disorders2/142
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/142
OsteonecrosisMusculoskeletal and connective tissue disorders2/142
Abscess jawInfections and infestations1/142
Atypical pneumoniaInfections and infestations1/142
Most frequent other events
Showing 10 of 46
Most frequent other events
EventOpen-label Belimumab 10 mg/kg
NasopharyngitisInfections and infestations86/142
HeadacheNervous system disorders40/142
CoughRespiratory, thoracic and mediastinal disorders26/142
Viral upper respiratory tract infectionInfections and infestations25/142
Herpes zosterInfections and infestations23/142
Abdominal pain upperGastrointestinal disorders23/142
NauseaGastrointestinal disorders23/142
Upper respiratory tract infectionInfections and infestations22/142
DiarrhoeaGastrointestinal disorders22/142
InfluenzaInfections and infestations20/142

Baseline characteristics

Baseline is the last available value prior to the first belimumab exposure.

Age, Continuous
Age, Continuous(Years)Open-label Belimumab 10 mg/kg
Mean34.6 ± 9.28
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Belimumab 10 mg/kg
Female129
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open-label Belimumab 10 mg/kg
American Indian or Alaskan Native1
Japanese Heritage71
East Asian Heritage68
Southeast Asian Heritage2
08

Study locations

27 sites
  • GSK Investigational Site
    Chiba, 275-8580, Japan
  • GSK Investigational Site
    Ehime, 791-0295, Japan
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Fukuoka, 810-8563, Japan
  • GSK Investigational Site
    Hiroshima, 730-8619, Japan
  • GSK Investigational Site
    Hiroshima, 739-0002, Japan
  • GSK Investigational Site
    Hokkaido, 060-8604, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Hyogo, 675-8545, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Nagasaki, 857-1195, Japan
  • GSK Investigational Site
    Okayama, 710-8522, Japan
  • GSK Investigational Site
    Okinawa, 901-0243, Japan
  • GSK Investigational Site
    Tochigi, 321-0293, Japan
  • GSK Investigational Site
    Tokyo, 104-8560, Japan
  • GSK Investigational Site
    Tokyo, 113-8431, Japan
  • GSK Investigational Site
    Tokyo, 160-8582, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Busan, 602-715, Korea, Republic of
  • GSK Investigational Site
    Busan, Korea, Republic of
  • GSK Investigational Site
    Daegu, 700-721, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400-711, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 133-792, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 150-713, Korea, Republic of
  • GSK Investigational Site
    Suwon, Kyonggi-do, 443-721, Korea, Republic of
09

References and documents

Publications

  • Tanaka Y, Bae SC, Bass D, Curtis P, Chu M, DeRose K, Ji B, Kurrasch R, Lowe J, Meizlik P, Roth DA. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 2021 Jul;7(2):e001629. doi: 10.1136/rmdopen-2021-001629. Erratum In: RMD Open. 2024 Jan 12;10(1):e001629corr1. doi: 10.1136/rmdopen-2021-001629corr1. PubMed 34215703 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Sep 2018, 75 months.

Results were first posted in Jan 2020, 1 year 3 months after primary completion.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 75 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2012
First posted
May 14, 2012
StartActual
Jun 11, 2012
Primary completionActual
Sep 13, 2018
CompletionActual
Sep 13, 2018
Results first posted
Jan 9, 2020
Last update
Mar 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01597622
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 14, 2012
Start date
Jun 11, 2012
Primary completion
Sep 13, 2018
Completion
Sep 13, 2018
Results posted
Jan 9, 2020
Last update
Mar 27, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion